Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data ; volume:23 ; number:1 ; day:11 ; month:1 ; year:2021 ; pages:1-9 ; date:12.2021
Arthritis Research & Therapy ; 23, Heft 1 (11.1.2021), 1-9, 12.2021
- Creator
-
Simon, Teresa A.
Dong, Lixian
Winthrop, Kevin L.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-020-02399-2
- URN
-
urn:nbn:de:101:1-2021030220255792198385
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Simon, Teresa A.
- Dong, Lixian
- Winthrop, Kevin L.
- SpringerLink (Online service)
Other Objects (12)
Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study
Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study
Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression
CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients
Abatacept vermindert Rezidivrisiko bei Riesenzellarteriitis
Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis
Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis
Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study
Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study
Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression
CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients
Abatacept vermindert Rezidivrisiko bei Riesenzellarteriitis
Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis
Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis
Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study
Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study
Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression
CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients
Abatacept vermindert Rezidivrisiko bei Riesenzellarteriitis
Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis